Sorrento Therapeutics Past Earnings Performance
Past criteria checks 0/6
Sorrento Therapeutics's earnings have been declining at an average annual rate of -27.1%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 5.2% per year.
Key information
-27.1%
Earnings growth rate
6.3%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 5.2% |
| Return on equity | n/a |
| Net Margin | -852.6% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sorrento Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 64 | -548 | 194 | 0 |
| 31 Mar 23 | 61 | -672 | 193 | 0 |
| 31 Dec 22 | 63 | -573 | 182 | 0 |
| 30 Sep 22 | 60 | -494 | 198 | 0 |
| 30 Jun 22 | 55 | -524 | 196 | 0 |
| 31 Mar 22 | 57 | -472 | 198 | 0 |
| 31 Dec 21 | 53 | -428 | 197 | 0 |
| 30 Sep 21 | 51 | -355 | 183 | 0 |
| 30 Jun 21 | 51 | -320 | 159 | 0 |
| 31 Mar 21 | 47 | -231 | 133 | 0 |
| 31 Dec 20 | 40 | -298 | 116 | 0 |
| 30 Sep 20 | 42 | -290 | 100 | 0 |
| 30 Jun 20 | 36 | -270 | 101 | 0 |
| 31 Mar 20 | 33 | -249 | 105 | 0 |
| 31 Dec 19 | 31 | -292 | 104 | 0 |
| 30 Sep 19 | 25 | -279 | 101 | 0 |
| 30 Jun 19 | 24 | -262 | 96 | 0 |
| 31 Mar 19 | 21 | -279 | 79 | 0 |
| 31 Dec 18 | 21 | -204 | 64 | 0 |
| 30 Sep 18 | 35 | -105 | 51 | 0 |
| 30 Jun 18 | 152 | -60 | 42 | 0 |
| 31 Mar 18 | 153 | 0 | 39 | 0 |
| 31 Dec 17 | 152 | 9 | 38 | 0 |
| 30 Sep 17 | 135 | -57 | 41 | 0 |
| 30 Jun 17 | 16 | -39 | 36 | 0 |
| 31 Mar 17 | 12 | -68 | 32 | 0 |
| 31 Dec 16 | 8 | -61 | 24 | 0 |
| 30 Sep 16 | 5 | -67 | 24 | 0 |
| 30 Jun 16 | 4 | -83 | 24 | 0 |
| 31 Mar 16 | 5 | -51 | 22 | 0 |
| 31 Dec 15 | 5 | -46 | 22 | 0 |
| 30 Sep 15 | 4 | -31 | 13 | 0 |
| 30 Jun 15 | 4 | -38 | 10 | 0 |
| 31 Mar 15 | 4 | -35 | 9 | 0 |
| 31 Dec 14 | 4 | -35 | 10 | 0 |
| 30 Sep 14 | 3 | -37 | 10 | 0 |
| 30 Jun 14 | 2 | -33 | 9 | 0 |
| 31 Mar 14 | 1 | -29 | 8 | 0 |
| 31 Dec 13 | 0 | -22 | 6 | 0 |
| 30 Sep 13 | 0 | -12 | 4 | 0 |
| 30 Jun 13 | 1 | -10 | 4 | 0 |
| 31 Mar 13 | 1 | -6 | 3 | 0 |
Quality Earnings: 0L85 is currently unprofitable.
Growing Profit Margin: 0L85 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0L85 is unprofitable, and losses have increased over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare 0L85's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0L85 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 0L85's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.